DGE 8th Decentralized & Hybrid Clinical Trials Conference to be Held in Philadelphia, PA

 Executives and professionals of the biopharma and medical device realm are invited to attend the 8th Decentralized & Hybrid Clinical Trial conference organized by DGE, May 15-16, 2024, in Philadelphia, PA. The event focuses on optimizing the technical processes, regulatory compliance, and design adaptability of remote clinical trials.

The conference is hosted by Dynamic Global Events (“DGE”), a Life Science leader in organizing b2b events. The global event company caters to the dynamic informational and networking needs of the pharmaceutical, biotechnology, healthcare, medical devices, and allied industries.

During COVID-19, remote and decentralized clinical trials (DCTs) came into practice. Since then, the application of decentralized methods for clinical trials has grown phenomenally. Thus, clinical trial teams have to be prepared and equipped to incorporate the relevant technologies for decentralized methods. This conference explores insights into challenges and offers solutions for selecting the right technologies for patients and sites, understanding FDA guidelines, overcoming logistical hurdles, and much more.

Experts conducting speaker sessions will also talk about how the power of AI can be harnessed for various clinical trial processes such as attaining patient data in DCTs, and also when solving issues of tech affordability, bias, and inconsistent data management. Additional topics include the importance of home sampling for decentralized trials, and uses of eConsent.

The event is meticulously curated to address challenges and offer solutions to the clinical trial industry. DGE offers a phenomenal networking platform to meet, learn, and connect with the right professionals and influencers. Connect with industry leaders, showcase unique ideas and presentations, and get the latest updates to stay ahead of the competition.

To know more, please visit https://nnw.fm/osmtO.

About NetworkNewsWire

NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer

NetworkNewsWire
New York, NY
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is powered by IBN

Golden Triangle Ventures Inc. (GTVH) New Acquisition Takes Lavish Division One Step Closer to Development of Premier Music, Art Destination

 

• More than half of Americans have attended a music festival, indicating lucrative potential for music and art destinations
• GTVH recently closed on the acquisition of ABI Create, a premier event-management and production company
• With the invaluable resources ABI Create brings to the table, the future of Destino Ranch looks more promising than ever

With Coachella still fresh in music lovers’ memories, it’s only natural to look at what other amazing music festivals might be looming in the future. Destino Ranch comes to mind. A new project focused on becoming an international destination where nature and technology combine to create unforgettable experiences such as outstanding music festivals, Destino Ranch is being developed by Golden Triangle Ventures (OTC: GTVH) and its entertainment division, Lavish Entertainment.

Officially called the Coachella Valley Music and Arts Festival, Coachella is held over two weekends at the Empire Polo Club in Indio, California, in the Coachella Valley in the Colorado Desert. The event traditionally features an array of musical artists from different music genres, including rock, pop, indie, hip hop and more; the festival also includes art installations and sculptures.

This year, Coachella saw record attendance, with organizers reporting an estimated 300,000 people flocking to Indio (https://nnw.fm/oGMmx). In addition, Coachella’s revenue is impressive, bringing in $115 million collectively from ticket, food and beverage sales and generating around $700 million for the local economy in Indio and surrounding cities each year (https://nnw.fm/3EbSM). 

There’s definitely an eager audience for events such as music and art festivals. In fact, a Marketing Chart study reported that “overall, roughly one-third (34%) of American adults surveyed report having been to more than one music festival, while an additional fifth (20%) say they’ve been once. As such, some 54% of U.S. adults have been to at least one music festival” (https://nnw.fm/B4MHS). 

Clearly, Golden Triangle Ventures and Lavish Entertainment are on to something. Most recently the company took a significant step forward in the development of Destino Ranch with the acquisition of ABI Create, a premier event-management and production company (https://nnw.fm/ZprKR). Founded by Marco Antonio Moreno, who was recently named president and COO of Lavish Entertainment, ABI Create has delivered high-quality productions for a range of large-scale installations at major music festivals, sporting events and conventions across the United States, including the NFL Super Bowl, San Diego and New York Comic Con events, EDC and Camp EDC, Bonnaroo Music Festival, the Waste Management Phoenix Open, Arnold Palmer Invitational, Burning Man and more.

The completed acquisition will transition ABI Create into a wholly owned subsidiary of Lavish Entertainment, strengthening Lavish’s position in the entertainment industry through ABI’s well-known reputation and proven track record of executing high-level projects. Headquartered in Las Vegas, ABI’s comprehensive suite of services includes event organization, management, production, logistics, site planning, permitting, construction, contracting, custom design and fabrication.

With the invaluable resources ABI Create brings to the table, the future of Destino Ranch looks more promising than ever. With access to nearly 22,000 visitors traveling through the area every day, the ranch could quickly become a modern art and music festival mecca. In fact, current plans call for the destination location to include an immersive, world-class art installation gallery with rotating exhibits as well as a large-scale music venue with state-of-the-art staging and production, all carefully designed to complement the beautiful natural attributes of the surrounding Mojave Desert.

“This acquisition of ABI Create sets the stage for us to begin showcasing all other synergistic divisions within Lavish that will support all resources, relationships and partnerships within the ABI portfolio of offerings,” said Steffan Dalsgaard, CEO of Golden Triangle Ventures. “Our goal is to develop ABI into a one-stop-shop, event-management business within Lavish that will hold a complete suite of event management and development services. This aims to complement all internal projects and productions and will potentially support outside business opportunities that can provide fundamental synergies to our ultimate plan of building a complete entertainment enterprise.”

Golden Triangle Ventures is a multifaceted consulting company that operates as a parent business pursuing ventures in the health, entertainment and technology sectors, as represented by the three-point golden triangle, along with other sectors that provide synergistic value to these three core divisions. The company aims to purchase, acquire and/or joint venture with established entities within these areas of business. The goods and services represented are driven by innovators who have passion and commitment in these marketplaces. The company plans to utilize relationships and create a platform for new and existing businesses to strengthen their products and/or services.

For more information, visit the company’s website at www.GoldenTriangleInc.com.

NOTE TO INVESTORS: The latest news and updates relating to GTVH are available in the company’s newsroom at https://nnw.fm/GTVH

About NetworkNewsWire

NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer

NetworkNewsWire
New York, NY
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is powered by IBN

SenesTech Inc.’s (NASDAQ: SNES) Evolve(TM) Soft Bait – New York’s Answer to the Growing Rat Problem

 

• SenesTech’s Evolve(TM) Soft Bait has been proposed to be used in New York City to control its growing rat population
• In a bill tabled by Upper West Side Council Member Shaun Abreu, the city will explore contraception for rats and will start with a 10-block area
• SenesTech’s CTO notes that the city should see close to complete elimination of the population in 12-18 months, not by just controlling the death rate, but by controlling the birth rate as well
• For SenesTech, this move helps affirm the superiority of its products. In addition, it serves as a sign of even bigger things to come

On Thursday, April 11, Flaco, an escaped zoo owl, was found dead with raised levels of rodenticide in his system in New York City, having consumed poisoned rats for sustenance. This was a wake-up call, highlighting the ineffectiveness of the current approach to controlling the city’s rat population and its cost to pets, wildlife, and birds of prey (https://nnw.fm/yFKMD). As a result, the event prompted involved parties to explore alternative, more effective, and more humane approaches to controlling this rat problem, with contraceptives proving to be the viable option.

SenesTech (NASDAQ: SNES), a rodent fertility control product and service provider, and the inventor of the only EPA-registered contraceptive for male and female rats, has been rapidly growing with its unique rodent control solutions, defined by its two main offerings – ContraPest(R) liquid, and Evolve(TM) Soft Bait, both of which have demonstrated impressive results in controlling pest populations through fertility control. The city of New York is exploring the use of Evolve, owing to its shelf life, safety profile and overall effectiveness.

Studies have shown that two rats alone can multiply to 15,000 in just one year. While poisoning and controlling their death rate has proven ineffective and dangerous for other animals, contraception is showing to be an excellent option to explore, particularly since, for a controlled population, one can achieve complete elimination in 12-18 months.

“If you’ve gotten the whole population on birth control, you should see close to a complete elimination of that population in 12 to 18 months. You’re not controlling the death rate. You’re controlling the birth rate,” noted Dan Palasky, SenesTech’s Chief Technical Officer (https://nnw.fm/aZtfv).

With the introduction of a new bill by an Upper West Side Council Member, the city is set to, hopefully once and for all, deal with the rat menace that has posed a challenge for every generation of New Yorkers. Various approaches have been explored, from the hiring of a “rat czar” in 2023 to the push to put trash out in boxes as opposed to bags to reduce the amount of food served up to rats (https://nnw.fm/Lkwnm). While it holds true that rodents can never be eradicated, contraception is a viable option in managing their population, all within a reasonable timeline. This is achieved without the risk of poisoning other animals, as was the case with Flaco.

“Rat birth control is a promising non-toxic solution to remediating heavily infested areas without dumping lethal poisons all over our city’s streetscape,” noted Shaun Abreu, an Upper West Side City Council Member.

“We can’t poison our way out of the rat problem, but we can certainly do a lot of damage trying,” he added.

Abreu’s pilot program is proposed to start with a 10-block area, with a six-month study to gain a baseline understanding of rodent populations. This will then be followed by six months of birth control. SenesTech is optimistic that its Evolve Soft Bait will yield impressive results over that period, highlighting the product’s overall efficacy while stamping the company’s position as a leader in its space. Already, the company has seen major interest in its Evolve product, and this move by the city of New York is seen as affirming the product’s superiority while serving as a sign of even bigger things to come.

For more information, visit the company’s website at www.SenesTech.com.

NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://nnw.fm/SNES

About NetworkNewsWire

NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer

NetworkNewsWire
New York, NY
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is powered by IBN

Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting the Massive Type 2 Diabetes and Obesity Markets with its DehydraTECH(TM) Technology

 

• Lexaria, a global innovator in drug delivery platforms, through its patented DehydraTECH(TM) technology, looks to address the growing type 2 diabetes and obesity problem
• Given the success of previous studies, the company is looking to double down on glucagon-like peptide 1 (“GLP-1”) studies for 2024
• GLP-1 treatments are a major player in managing weight and addressing diabetes, and Lexaria’s DehydraTECH(TM) drug delivery platform has the potential of replacing painful and expensive GLP-1 injections with an effective oral delivery path
• The company has already received independent ethics review board approval for its GLP-1 human pilot study #2, a milestone that brings it closer to offering a tolerable oral delivery option for diabetes treatment

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recognizes the tremendous potential in the treatment of type 2 diabetes and obesity, and looks to address it through its patented DehydraTECH(TM) drug delivery technology that offers improved delivery of bioactive compounds. The confidence in its technology, as evidenced by the success of previous clinical studies, has allowed it to double down on glucagon-like peptide 1 (“GLP-1”) studies for the 2024 calendar year. The company is optimistic that the studies will yield positive results, not just in the potential treatment of diabetes but also in weight management, which has been directly linked to diabetes.

According to the Centers for Disease Control and Prevention (“CDC”), more than one in three Americans today are at increased risk for type 2 diabetes. This represents about 98 million Americans, with 81% not knowing they are at such a risk (https://nnw.fm/FMg4v). Studies showed a massive spike in overall incidences of type 2 diabetes between 2002 and 2018, with one of the main cited risk factors being obesity. The CDC noted that of those diagnosed with the condition, 89.8% of them were overweight or obese, as defined by a body mass index (“BMI”) of 25 kg/m2 or higher. This was further compounded by physical inactivity, with 31.9% of those diagnosed reporting getting less than 10 minutes a week of moderate or vigorous activity (https://nnw.fm/jhDFA). 

In March, Lexaria announced details of its upcoming 12-week animal study WEIGHT-A24-1 that will examine diabetes and weight loss effects of DehydraTECH-processed GLP-1 drugs and DehydraTECH-processed cannabidiol, alone and in combination (https://nnw.fm/UpfIW). Results will guide additional human investigations.

The company recently received independent third-party ethics review board approval for its GLP-1 human pilot study #2, seeking to explore the oral delivery of GLP-1 drugs. For Lexaria, this marks a significant milestone that brings it closer to offering a more effective and tolerable oral delivery option for diabetes treatment and weight loss management (https://nnw.fm/57LmL).

“Most GLP-1 drugs sold today are administered by painful and expensive injection devices. More effective and tolerable oral delivery of GLP-1 drugs could be extremely valuable to patients and to industry,” noted Chris Bunka, Lexaria’s CEO.

“I am excited about this study; the Lexaria scientific team believes that a dissolvable oral tablet that delivers an effective fraction of semaglutide along with reduced side effects could potentially offer valuable benefits to the pharmaceutical industry that might lead to a higher likelihood of favorable strategic partnering with leading industry players in GLP-1,” he added.

Previous Lexaria studies have demonstrated that DehydraTECH processing results in higher brain absorption than non-DehydraTECH arms. Already, GLP-1R agonists have been shown to penetrate the brain and activate a subset of GLP-1R-expressing neurons in the arcuate nucleus to produce weight loss. With the upcoming studies, Lexaria looks to evidence that DehydraTECH processing of GLP-1 drugs can enable even faster penetration into brain tissue, ultimately improving overall efficiency in weight loss and blood sugar control. Its management is optimistic that it will replicate the success of previous studies and looks forward to kickstarting the undertaking.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX

About NetworkNewsWire

NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer

NetworkNewsWire
New York, NY
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is powered by IBN